Mueller et al. (32) showed that combined therapy with dual-targeting of Ang-2 and VEGF significantly inhibits tumor activity and that compared to single-targeted therapy of Ang-2 or VEGF, combined therapy has obvious advantages. The gene discussed is ANGPT2; the disease is neoplasm.